Mannkind (MNKD) Gains from Sales and Divestitures (2012 - 2026)
Mannkind (MNKD) reported Gains from Sales and Divestitures of $246822.0 for Q1 2026, down 94.32% quarter-over-quarter from $4.3 million in Q4 2025.
Mannkind (MNKD) Gains from Sales and Divestitures (2012 - 2026) Analysis & Trends
Mannkind (MNKD) has 15 years of Gains from Sales and Divestitures data on file, last reported at $246822.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $246822.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $246822.0 (changed N/A YoY), and the FY2025 annual result was $4.3 million, down 0.69% from the prior year.
- Gains from Sales and Divestitures retreated to $246822.0 in Q1 2026 per MNKD's latest filing, from $4.3 million in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $6.1 million in Q4 2023 and troughed at $246822.0 in Q1 2026.
- A 5-year average of $3.3 million and a median of $4.3 million in 2025 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2023 and 2024: Gains from Sales and Divestitures jumped 290.26% in 2023, then fell 27.65% in 2024.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $1.6 million in 2022, then jumped by 290.26% to $6.1 million in 2023, then slipped by 27.65% to $4.4 million in 2024, then retreated by 0.69% to $4.3 million in 2025, then tumbled by 94.32% to $246822.0 in 2026.
- Business Quant data shows MNKD's Gains from Sales and Divestitures at $246822.0 in Q1 2026, $4.3 million in Q4 2025, and $4.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 246,822.00 |
| Mar 31, 2026 | 246,822.00 |
| Dec 31, 2025 | 4.35 Mn |
| Dec 31, 2025 | 4.35 Mn |
| Dec 31, 2024 | 4.38 Mn |
| Dec 31, 2024 | 4.38 Mn |
| Dec 31, 2023 | 6.05 Mn |
| Dec 31, 2023 | 6.05 Mn |
| Dec 31, 2022 | 1.55 Mn |
| Dec 31, 2022 | 1.55 Mn |
| Dec 31, 2021 | 1.52 Mn |
| Dec 31, 2021 | 1.52 Mn |
| Dec 31, 2020 | 1.73 Mn |
| Dec 31, 2020 | 1.73 Mn |
| Dec 31, 2019 | 804,105.00 |
| Dec 31, 2019 | 804,105.00 |
| Dec 31, 2018 | 694,831.00 |
| Dec 31, 2018 | 694,831.00 |
| Dec 31, 2017 | 192,361.00 |
| Dec 31, 2017 | 192,361.00 |